Pharmacogenetic Analysis of Pediatric Patients with Acute Lymphoblastic Leukemia: A Possible Association between Survival Rate and ITPA Polymorphism

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Kim, Hyery ^a   Kang, Hyoung Jin ^a   Kim, Hyo Jeong ^a   Jang, Mi Kyung ^a   Kim, Nam Hee ^a   Oh, Yongtaek ^b   Han, Byoung Don ^b   Choi, Ji Yeob ^a   Kim, Chul Woo ^a   Lee, Ji Won ^a   Park, Kyung Duk ^a   Shin, Hee Young ^a   Ahn, Hyo Seop ^a  

^a Seoul National University College of Medicine   (South Korea)

^b YeBT Co LTD   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; HYDROCORTISONE; MERCAPTOPURINE; METHOTREXATE; METHYLENETETRAHYDROFOLATE DEHYDROGENASE; MULTIDRUG RESISTANCE PROTEIN 1; THIOPURINE METHYLTRANSFERASE; THYMIDYLATE SYNTHASE; VITAMIN D RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CHILD; CYP3A4 GENE; CYP3A5 GENE; DRUG DOSE REDUCTION; DRUG EFFICACY; ETHNIC DIFFERENCE; EXON; FEBRILE NEUTROPENIA; FEMALE; GENE ACTIVITY; GENE FREQUENCY; GENE FUNCTION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GSTM1 GENE; GSTP1 GENE; GSTT1 GENE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; INFANT; INTRON; ITPA GENE; MAJOR CLINICAL STUDY; MALE; MDR1 GENE; MTHFR 1298 GENE; MTHFR 677 GENE; MULTIVARIATE ANALYSIS; NR3C1 GENE; ONCOGENE; OUTCOME ASSESSMENT; PHARMACOGENETICS; PRESCHOOL CHILD; RFC1 GENE; RISK FACTOR; SCHOOL CHILD; SEPSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TPMT GENE; TYMS GENE; VDR GENE; VEIN OCCLUSION; VIRUS PNEUMONIA;

ADOLESCENT; ALLELES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; CHILD; CHILD, PRESCHOOL; FEMALE; GENE FREQUENCY; GENOTYPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MALE; METHYLTRANSFERASES; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; PYROPHOSPHATASES;

EID: 84866722399     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045558     Document Type: Article

References (39)

1. Pui CH, Robison LL, Look AT, (2008) Acute lymphoblastic leukaemia. Lancet 371: 1030-1043.
2. Evans WE, McLeod HL, (2003) Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 348: 538-549.
3. Pollock BH, DeBaun MR, Camitta BM, Shuster JJ, Ravindranath Y, et al. (2000) Racial differences in the survival of childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group Study. J Clin Oncol 18: 813-823.
4. Phillips EM, Odunlami AO, Bonham VL, (2007) Mixed Race: Understanding Difference in the Genome Era. Soc Forces 86: 795-820.
5. Hutchinson RJ, Gaynon PS, Sather H, Bertolone SJ, Cooper HA, et al. (2003) Intensification of therapy for children with lower-risk acute lymphoblastic leukemia: long-term follow-up of patients treated on Children's Cancer Group Trial 1881. J Clin Oncol 21: 1790-1797.
6. Lange BJ, Bostrom BC, Cherlow JM, Sensel MG, La MK, et al. (2002) Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 99: 825-833.
7. Broxson EH, Dole M, Wong R, Laya BF, Stork L, (2005) Portal hypertension develops in a subset of children with standard risk acute lymphoblastic leukemia treated with oral 6-thioguanine during maintenance therapy. Pediatr Blood Cancer 44: 226-231.
8. Gaynon PS, Angiolillo AL, Carroll WL, Nachman JB, Trigg ME, et al. (2010) Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children's Oncology Group Report. Leukemia 24: 285-297.
9. Stocco G, Crews KR, Evans WE, (2010) Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status. Expert Opin Drug Saf 9: 23-37.
10. Stocco G, Cheok MH, Crews KR, Dervieux T, French D, et al. (2009) Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther 85: 164-172.
11. Rocha JC, Cheng C, Liu W, Kishi S, Das S, et al. (2005) Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood 105: 4752-4758.
12. Cunningham L, Aplenc R, (2007) Pharmacogenetics of acute lymphoblastic leukemia treatment response. Expert Opin Pharmacother 8: 2519-2531.
13. Felix CA, Walker AH, Lange BJ, Williams TM, Winick NJ, et al. (1998) Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci U S A 95: 13176-13181.
14. Whitfield GK, Jurutka PW, Haussler CA, Haussler MR, (1999) Steroid hormone receptors: evolution, ligands, and molecular basis of biologic function. J Cell Biochem Suppl 32-33: 110-122.
15. Relling MV, Hancock ML, Boyett JM, Pui CH, Evans WE, (1999) Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood 93: 2817-2823.
16. Goldman ID, Matherly LH, (1985) The cellular pharmacology of methotrexate. Pharmacol Ther 28: 77-102.
17. Wang W, Marsh S, Cassidy J, McLeod HL, (2001) Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors. Cancer Res 61: 5505-5510.
18. Distelhorst CW, (2002) Recent insights into the mechanism of glucocorticosteroid-induced apoptosis. Cell Death Differ 9: 6-19.
19. Kang HJ, Oh Y, Chun SM, Seo YJ, Shin HY, et al. (2008) TotalPlex gene amplification using bulging primers for pharmacogenetic analysis of acute lymphoblastic leukemia. Mol Cell Probes 22: 193-200.
20. Huang MY, Fang WY, Lee SC, Cheng TL, Wang JY, et al. (2008) ERCC2 2251A>C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: a preliminary study. BMC Cancer 8: 50.
21. Marinaki AM, Ansari A, Duley JA, Arenas M, Sumi S, et al. (2004) Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics 14: 181-187.
22. Gao LB, Pan XM, Li LJ, Liang WB, Bai P, et al. (2011) Null genotypes of GSTM1 and GSTT1 contribute to risk of cervical neoplasia: an evidence-based meta-analysis. PLoS One 6: e20157.
23. Xiang Q, Zhao X, Zhou Y, Duan JL, Cui YM, (2010) Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety. J Clin Pharmacol 50: 659-666.
24. Wu L, Xu X, Shen J, Xie H, Yu S, et al. (2007) MDR1 gene polymorphisms and risk of recurrence in patients with hepatocellular carcinoma after liver transplantation. J Surg Oncol 96: 62-68.
25. Aplenc R, Thompson J, Han P, La M, Zhao H, et al. (2005) Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia. Cancer Res 65: 2482-2487.
26. Cheok MH, Evans WE, (2006) Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nat Rev Cancer 6: 117-129.
27. Adam de Beaumais T, Jacqz-Aigrain E, (2012) Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia. Eur J Clin Pharmacol.
28. Stanulla M, Schaeffeler E, Flohr T, Cario G, Schrauder A, et al. (2005) Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA 293: 1485-1489.
29. Dorababu P, Nagesh N, Linga VG, Gundeti S, Kutala VK, et al. (2012) Epistatic interactions between thiopurine methyltransferase (TPMT) and inosine triphosphate pyrophosphatase (ITPA) variations determine 6-mercaptopurine toxicity in Indian children with acute lymphoblastic leukemia. Eur J Clin Pharmacol 68: 379-387.
30. Hahn LW, Ritchie MD, Moore JH, (2003) Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. Bioinformatics 19: 376-382.
31. Ritchie MD, Hahn LW, Moore JH, (2003) Power of multifactor dimensionality reduction for detecting gene-gene interactions in the presence of genotyping error, missing data, phenocopy, and genetic heterogeneity. Genet Epidemiol 24: 150-157.
32. de Wildt SN, (2011) Profound changes in drug metabolism enzymes and possible effects on drug therapy in neonates and children. Expert Opin Drug Metab Toxicol 7: 935-948.
33. Ganiere-Monteil C, Medard Y, Lejus C, Bruneau B, Pineau A, et al. (2004) Phenotype and genotype for thiopurine methyltransferase activity in the French Caucasian population: impact of age. Eur J Clin Pharmacol 60: 89-96.
34. Stevens JC, Hines RN, Gu C, Koukouritaki SB, Manro JR, et al. (2003) Developmental expression of the major human hepatic CYP3A enzymes. J Pharmacol Exp Ther 307: 573-582.
35. Tanaka Y, Kurosaki M, Nishida N, Sugiyama M, Matsuura K, et al. (2011) Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C. Hum Mol Genet 20: 3507-3516.
36. Wu J, Lei G, Mei M, Tang Y, Li H, (2010) A novel C53/LZAP-interacting protein regulates stability of C53/LZAP and DDRGK domain-containing Protein 1 (DDRGK1) and modulates NF-kappaB signaling. J Biol Chem 285: 15126-15136.
37. Marsh S, Van Booven DJ, (2009) The increasing complexity of mercaptopurine pharmacogenomics. Clin Pharmacol Ther 85: 139-141.
38. Kadan-Lottick NS, Ness KK, Bhatia S, Gurney JG, (2003) Survival variability by race and ethnicity in childhood acute lymphoblastic leukemia. JAMA 290: 2008-2014.
39. Bhatia S, Sather HN, Heerema NA, Trigg ME, Gaynon PS, et al. (2002) Racial and ethnic differences in survival of children with acute lymphoblastic leukemia. Blood 100: 1957-1964.